The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
Agios Pharmaceuticals, Inc. COM 00847X104 178,473 3,895,090 SH   DFND   3,895,090 0 0
bluebird bio, Inc. COM 09609G100 93,223 2,416,974 SH   DFND   2,416,974 0 0
Eleven Biotherapeutics, Inc. COM 286221106 63,812 4,841,591 SH   DFND   4,841,591 0 0
Foundation Medicine, Inc. COM 350465100 132,838 4,927,234 SH   DFND   4,927,234 0 0